Table 2. Survival estimates by patient characteristics.

	N Patients	N Events	5-year overall survival estimate (95% CI)	P-value	N Events	5-year relapse-tree survival estimate (95% CI)	P-value
All patients	589	38	0.93 (0.9, 0.95)		61	0.87 (0.84, 0.9)
Year of diagnosis
2001–2006	142	14	0.92 (0.86, 0.96)		19	0.88 (0.82, 0.93)
2007–2012	447	24	0.93 (0.89, 0.95)	0.60	42	0.86 (0.8, 0.9)	0.64
Age (years)
Age≤50	293	19	0.93 (0.88, 0.96)		30	0.87 (0.82, 0.91)
Age>50	296	19	0.92 (0.88, 0.95)	0.78	31	0.87 (0.82, 0.91)	0.80
Race/ethnicity
White	344	23	0.92 (0.88, 0.95)		33	0.89 (0.85, 0.92)
Black	73	6	0.89 (0.77, 0.95)		13	0.72 (0.55, 0.84)
Hispanic	116	4	0.98 (0.92, 0.99)		7	0.92 (0.83, 0.96)
Other	56	5	0.87 (0.71, 0.95)	0.39	8	0.84 (0.71, 0.92)	0.03
Clinical stage
I–II	301	17	0.93 (0.89, 0.96)		22	0.9 (0.85, 0.94)
III	282	20	0.92 (0.87, 0.95)	0.42	38	0.84 (0.79, 0.88)	0.01
Histology
Ductal	543	34	0.93 (0.9, 0.95)		54	0.88 (0.84, 0.91)
Other	46	4	0.91 (0.74, 0.97)	0.56	7	0.82 (0.64, 0.92)	0.26
Nuclear grade
1–2	123	7	0.93 (0.84, 0.97)		14	0.86 (0.76, 0.92)
3	452	30	0.93 (0.89, 0.95)	0.57	45	0.88 (0.84, 0.91)	0.71
Lymphovascular invasion
Negative	479	24	0.94 (0.91, 0.96)		37	0.9 (0.87, 0.93)
Positive	110	14	0.86 (0.76, 0.92)	0.002	24	0.72 (0.6, 0.81)	<0.0001
Hormone receptor status
Negative	236	18	0.92 (0.86, 0.95)		24	0.88 (0.82, 0.92)
Positive	348	20	0.93 (0.89, 0.96)	0.53	36	0.87 (0.82, 0.91)	0.77
Pathologic complete response
No	386	33	0.9 (0.85, 0.93)		54	0.83 (0.78, 0.87)
Yes	203	5	0.98 (0.93, 0.99)	0.002	7	0.95 (0.9, 0.98)	<0.0001
Adjuvant trastuzumab
No	109	11	0.91 (0.84, 0.95)		12	0.92 (0.85, 0.96)
Yes	480	27	0.93 (0.9, 0.95)	0.97	49	0.85 (0.8, 0.89)	0.33
Adjuvant radiation
No	125	8	0.94 (0.86, 0.97)		10	0.89 (0.79, 0.95)
Yes	464	30	0.92 (0.89, 0.95)	0.69	51	0.87 (0.83, 0.9)	0.63
Adjuvant endocrine therapy
No	301	23	0.91 (0.87, 0.94)		31	0.87 (0.82, 0.91)
Yes	288	15	0.94 (0.89, 0.96)	0.17	30	0.87 (0.82, 0.91)	0.84

Abbreviation: CI=confidence interval.